B. Riley Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani maintains a Neutral rating on Madrigal Pharmaceuticals (MDGL) and lowers the price target from $270 to $200.
May 10, 2024 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Madrigal Pharmaceuticals' price target was reduced from $270 to $200 by B. Riley Securities, while maintaining a Neutral rating.
A reduction in the price target by a significant margin suggests a bearish outlook on the stock's short-term price potential, likely leading to negative investor sentiment and a potential decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100